安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
- Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . .
Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
- Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs. com
Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in adults not taking a statin who have known heart disease or are at
- Nexletol shows CLEAR benefit in cardiovascular outcome trial
New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
- Statin alternative lowers heart-related deaths - Harvard Health
The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
- Nexletol From Esperion - Pharmacy Times
The FDA has approved broad new label expansions for bempedoic acid (Nexletol; Esperion Therapeutics, Inc) to reduce the risk of myocardial infarction and coronary revascularization in adults with established cardiovascular disease (CVD) or a high risk for a CVD event who are unable to use statin therapy The medication is also approved as an adjunct to diet, alone or in combination with other
- U. S. FDA Approves Broad New Labels for NEXLETOL and . . . - DAIC
April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention
- In the CLEAR‑Outcomes trial, what bempedoic acid (Nexletol . . .
The median follow-up duration was 40 6 months (3 4 years), with 95 3% of patients followed until trial end or death 3, 4 The trial definitively established that bempedoic acid reduces cardiovascular events in statin-intolerant patients, filling a critical treatment gap for this challenging population 5, 8, 7 The American College of Cardiology
|
|
|